Vaccine against COVID-19 or against SARS-CoV-2 infection?

IF 0.2 Q4 ALLERGY

Alergologia Polska - Polish Journal of Allergology Pub Date : 2020-01-01 DOI:10.5114/pja.2020.97913

P. Rieske

引用次数: 4

Abstract

Article offers analysis of main aspects of SARS-CoV-2/COVID-19 vaccination (severe acute respiratory syndrome coronavirus 2/COVID-19-Coronavirus Disease 2019) Optimal vaccine should protect not only against disease COVID-19 (symptoms), but also against SARS-CoV-2 infection (spreading disease) However, this kind of vaccine – showing highest safety level is extremely difficult to get Several additional SARS-CoV-2/COVID-19 vaccination issues were addressed in article For example: serological passports, herd immunity, clinical trials, and role of antibodies and T cells crossreactivities Article discusses some issues related to vaccination responsibilities

查看原文本刊更多论文

预防COVID-19或SARS-CoV-2感染的疫苗?

文章分析了SARS-CoV-2/COVID-19疫苗接种(严重急性呼吸综合征冠状病毒2/COVID-19冠状病毒病2019)的主要方面。最佳疫苗不仅应预防COVID-19疾病(症状)，还应预防SARS-CoV-2感染(传播疾病)。然而，这种显示最高安全水平的疫苗极其难以获得。血清学护照、群体免疫、临床试验以及抗体和T细胞交叉反应的作用本文讨论了与疫苗接种责任有关的一些问题

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.